# Leaders Free III: BioFreedom™ Clinical Trial

Study · id `cardio:ct-nct03118895` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03118895](<https://clinicaltrials.gov/study/NCT03118895>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03118895

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 404 participants.

## Technical summary

Registry record NCT03118895. Allocation not applicable; no masking; primary purpose treatment. Start 2017-11-08 (actual); primary completion 2019-09-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 404 participants (enrolled count; ClinicalTrials.gov record NCT03118895, source copy `cardio:ctgov-nct03118895-2024-02-29`, retrieved 2026-10-26)
- Started: 2017-11-08 (actual) (ClinicalTrials.gov record NCT03118895, source copy `cardio:ctgov-nct03118895-2024-02-29`, retrieved 2026-10-26)
- Primary completion: 2019-09-05 (actual) (ClinicalTrials.gov record NCT03118895, source copy `cardio:ctgov-nct03118895-2024-02-29`, retrieved 2026-10-26)
- Completion: 2022-11-18 (actual) (ClinicalTrials.gov record NCT03118895, source copy `cardio:ctgov-nct03118895-2024-02-29`, retrieved 2026-10-26)
- Countries: France; Switzerland (ClinicalTrials.gov record NCT03118895, source copy `cardio:ctgov-nct03118895-2024-02-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03118895-2024-02-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Leaders Free III: BioFreedom™ Clinical Trial
- Condition: Cardiac Death
- Condition: Myocardial Infarction
- Condition: Stent Thrombosis
- Condition: Bleeding
- Condition: Mortality
- Intervention (Device): BioFreedom™ BA9™ drug-coated stent
- Lead sponsor: Biosensors Europe SA
- Lead sponsor class: INDUSTRY
- Collaborator: European Cardiovascular Research Center
- Collaborator class: NETWORK

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Biosensors Europe SA (`cardio:org-biosensors-europe-sa`)
- Registry lists this organization as a collaborator: European Cardiovascular Research Center (`cardio:org-european-cardiovascular-research-center`)

## Provenance

Content hash: 3d6c61d2e0adc310946edcb364de9b9555b9d16ca4849cc2439d8ac8f8181cb9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
